Hepatic Oncology

Hepat Oncol

2045-0923

2045-0931

Therapeutic Area

Diagnostic Imaging, Health Economics/Outcomes Research, Hepatology, Immunology, Internal Medicine, Oncology, Pain Management, Pathology, Pediatrics, Pharmacoeconomics, Radiology, Research, Surgery

Gastroenterologists, Health Scientists, Hepatologists, Oncologists, Pathologists, Pharmaco-Epidemiologists, Pharmacologists, Physicians, Physicians - Medicine, Radiation Oncologists, Researchers, Surgeons, Surgical Oncologists

Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver, Clinical trials in hepatic oncology, Diagnosis and imaging, Epidemiology, Palliative care, Pathogenesis, Pathology, Pediatrics, Pharmacoeconomics, outcomes and comparative effectiveness research, Prognosis, Risk factors, Staging, Surveillance, Therapy, including surgery, chemotherapy, chemoembolization, ablation, radiotherapy, hormonal and biological therapies, Translational research and biomarker studies.

No associations affiliated with this journal

Future Medicine Ltd.

Electronic Circulation Submission to Acceptance Acceptance to Online Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines